Regenxbio RGNX Repayments Under Royalty Monetization Liabilities Net Of Interest
Repayments Under Royalty Monetization Liabilities Net Of Interest at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept rgnx:RepaymentsUnderRoyaltyMonetizationLiabilitiesNetOfInterest.
The official record: Regenxbio’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regenxbio's repayments under royalty monetization liabilities net of interest.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regenxbio's repayments under royalty monetization liabilities net of interest?
- Regenxbio (RGNX) reported repayments under royalty monetization liabilities net of interest of $13.38M in Q1 2026.
- How has Regenxbio's repayments under royalty monetization liabilities net of interest changed year-over-year?
- Regenxbio's repayments under royalty monetization liabilities net of interest increased by 139.1% year-over-year, from $5.59M to $13.38M.
- What does repayments under royalty monetization liabilities net of interest mean?
- This metric represents the cash outflows associated with the principal repayment of debt obligations structured as royalty monetization agreements. It reflects the company's commitment to settle financial liabilities tied to future revenue streams from specific therapeutic assets or intellectual property. Monitoring this helps investors assess the company's leverage and the impact of non-dilutive financing structures on long-term cash flow.